Getting Ahead of the ALS Curve Through Early Detection and Intervention: Module 1

To claim CME/NCPD visit this link: https://bit.ly/4eOeFcm

0.5 CME | 0.5 NCPD | MOC | ILNA

STATEMENT OF NEED

Amyotrophic lateral sclerosis (ALS) is a neurological disorder in which motor neurons deteriorate and result in muscle atrophy. As the disease progresses, affected individuals lose control of voluntary movements such as breathing, walking, talking, and chewing. Because treatments for slowing progression may be most effective earlier in the disease course, it is vital that patients with ALS are diagnosed as quickly as possible. While physical exams, neurologic exams, and muscle and imaging tests can help to support diagnosis, there is no single test for definitively diagnosing ALS (NIH, 2024). Therefore, it is crucial that members of the interdisciplinary healthcare team be familiar with risk factors and early symptoms of ALS in order to enable timely diagnosis and improve patient outcomes. In Module 1 of this microlearning series and podcast, Dr. Sabrina Paganoni, Co-Director of the Neurological Clinical Research Institute at Massachusetts Hospital and Healey & AMG Center for ALS, and Associate Professor of Physical Medicine and Rehabilitation (PM&R) at Spaulding Rehabilitation Hospital of Harvard Medical School, will share strategies for getting ahead of the ALS curve by enabling earlier detection.

TARGET AUDIENCE

Primary care physicians (PCPs), neurologists, nurse practitioners, physician assistants, nurses, pharmacists, and other health care professionals involved in the treatment of patients with amyotrophic lateral sclerosis (ALS).

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

Evaluate factors that can inform an early and accurate diagnosis of ALS

There is no fee to participate in or claim CME/NCPD credit for this activity.

DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES

i3 Health endorses the standards of the ACCME and ANCC that require everyone in a position to control the content of a CME/NCPD activity to disclose all financial relationships with ineligible companies that are related to the content of the CME/NCPD activity. CME/NCPD activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.

A conflict of interest is created when an individual has an opportunity to affect CME/NCPD content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.

i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.

Relevant financial relationships exist between the following individuals and ineligible companies:

The i3 Health planners, reviewers, and managers have nothing to disclose.

Sabrina Paganoni, MD, PhD, discloses that she has served as a sonsultant for Amylyx, Arrowhead, Cytokinetics, and Eikonizo, and she has received grants/research support from Calico, Clene, Denali, Prilenia, Seelos, and UCB.

i3 Health has mitigated all relevant financial relationships.

COMMERCIAL SUPPORT

This activity is supported by an independent medical educational grant from Amylyx Pharmaceuticals, Inc.